Ando, Masashi http://orcid.org/0000-0002-9537-8879
Honda, Kazunori
Hosoda, Waki
Matsubara, Yuki
Kumanishi, Ryosuke
Nakazawa, Taiko
Ogata, Takatsugu
Nakata, Akinobu
Kodama, Hiroyuki
Masuishi, Toshiki
Narita, Yukiya
Taniguchi, Hiroya
Kadowaki, Shigenori
Muro, Kei
Article History
Received: 4 October 2022
Accepted: 12 February 2023
First Online: 10 March 2023
Declarations
:
: M Ando reports honoraria for lectures from Eisai Co., Ltd., Ono Pharmaceutical Co.,Ltd., Chugai Pharmaceutical Co., Ltd., Mundipharma Co., Ltd., and Taiho Pharmaceutical Co., Ltd. K Honda reports grants or contracts from Chugai Pharmaceutical Co., Ltd., and Taiho Pharmaceutical Co., Ltd. W Hosoda reports no conflicts of interest. Y Matsubara reports honoraria for lectures from Taiho Pharmaceutical Co., Ltd., Bristol Myers Squibb, Eli Lilly Japan K.K., Takeda Pharmaceutical Co. Ltd., and Merck Biopharma Co., Ltd. R Kumanishi reports no conflicts of interest. T Nakazawa reports honoraria for lectures from Eli Lilly Japan K.K. T Ogata reports honoraria for lectures from Ono Pharmaceutical Co.,Ltd., Taiho Pharmaceutical Co., Ltd., and Bristol Myers Squibb. A Nakata reports no conflicts of interest. H Kodama reports no conflicts of interest. T Masuishi reports grants or contracts from MSD K.K., Daiichi Sankyo Co.,Ltd., Ono Pharmaceutical Co.,Ltd., Novartis Pharma K.K., Amgen Inc., Syneos Health Clinical K.K., Boehringer Ingelheim, Pfizer Inc., CIMIC Shift Zero K.K., and Eli Lilly Japan K.K.; honoraria for lectures from Takeda Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co., Ltd., Merck Biopharma Co. Ltd., Taiho Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Eli Lilly Japan K.K., Yakult Honsha Co., Ltd., Sanofi K.K., Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co.,Ltd., and Bristol Myers Squibb. Y Narita reports grants or personal fees from Ono Pharmaceutical Co.,Ltd., and Bristol Myers Squibb; honoraria for lectures, presentations, or speaker bureaus from Yakult Honsha Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., and Astra Zeneca. H Taniguchi reports grants or contracts from Takeda Pharmaceutical Co. Ltd., Daiichi Sankyo Co.,Ltd., and Ono Pharmaceutical Co.,Ltd.; honoraria for lectures, presentations, or speaker bureaus from Takeda Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Merck Biopharma Co. Ltd., Ono Pharmaceutical Co.,Ltd., and Chugai Pharmaceutical Co., Ltd. S Kadowaki reports grants or contracts from Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Chugai Pharmaceutical Co., Ltd., Nobelpharma Co., Ltd., Ono Pharmaceutical Co.,Ltd., Daiichi Sankyo Co., Ltd., and Janssen Pharma K.K.; honoraria for lectures from Eli Lilly Japan K.K., Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co.,Ltd., Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Merck Biopharma Co. Ltd., Daiichi Sankyo Co., Ltd., and Eisai Co., Ltd. K Muro reports study funding and support for Medical Writing/editing from Astellas Pharma Inc., and OPEN Health; grants or contracts from Solasia Pharma Inc., Merck Biopharma Co. Ltd., Daiichi Sankyo Co., Ltd., Parexel International Inc., Pfizer Inc., MSD K.K., Amgen Inc., Ono Pharmaceutical Co.,Ltd., Astellas Pharma Inc., Sanofi K.K., Taiho Pharmaceutical Co., Ltd., and Eisai Co., Ltd.; consulting fees from Astra Zeneca, Ono Pharmaceutical Co.,Ltd., and Amgen Inc.; honoraria for lectures, presentations, or speakers bureaus from Ono Pharmaceutical Co.,Ltd., Taiho Pharmaceutical Co., Ltd., Bristol Myers Squibb, and Eli Lilly Japan K.K.; participation on a Data Safety Monitoring Board or Advisory Board from Ono Pharmaceutical Co.,Ltd., MSD K.K., Astra Zeneca, Daiichi Sankyo Co., Ltd., and Solasia Pharma Inc.
: Informed consent requirement was waived due to the study’s observational retrospective design, with an opt-out opportunity provided at the institutional website.